Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 08, 2024 17:00 ET | Source: https://immatics.com/

Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME

Two oral presentations and multiple posters on clinical andpreclinical-stage candidates to be presented at SITC, demonstratingthe strength of Immatics’ TCR-T PRAME franchise to target solid cancers ...
October 10, 2022 07:36 ET | Source: Immatics N.V.

Immatics veröffentlicht Daten aus laufender Phase-1-Zelltherapie-Studie ACTengine® IMA203 TCR-T-Monotherapie gegen die Zielstruktur PRAME

Live-Webcast am Montag, den 10. Oktober, um 14:30 Uhr MESZ Klinische Validierung von PRAME als Multi-Tumor-Zielstruktur mit großem Potenzial für TCR-basierte Zelltherapien: Bestätigte...
October 10, 2022 07:36 ET | Source: https://immatics.com/

Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME

Company to host conference call today, October 10, at 8:30 am EDT / 2:30 pm CEST Clinical validation of PRAME as multi-tumor target with large potential for TCR-based therapies: confirmed responses...